July 30, 2025Open Access

Understanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment

View Full Paper

Ask AI

Bookmark

Authors

SPSupriya PeshinNorton Community Hospital ADAdit DhariaHigh Point University JKJasmeet KaurGovernment Medical College

Discussion

Member takes

Implication

This review demonstrates the impact of chemotherapy-induced thrombocytopenia on gastrointestinal cancer treatment, suggesting management strategies through thrombopoietin receptor agonists and dose modification.

Key Points

Chemotherapy-induced thrombocytopenia affects 20-25% of solid tumor patients, particularly those on oxaliplatin regimens.
Oxaliplatin can cause acute and chronic thrombocytopenia via immune mechanisms or marrow suppression.
Current management strategies include dose modifications, transfusions, and thrombopoietin receptor agonists like romiplostim.
Ongoing research into novel agents targeting megakaryopoiesis holds potential for improved long-term outcomes in CIT management.

Cite This Study

Peshin et al. (2025) studied this question.

synapsesocial.com/papers/689a0945e6551bb0af8cf038 https://doi.org/10.20944/preprints202507.2232.v1

View Full Paper

Ask AI

Bookmark

Understanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment

Discussion

Member takes

Implication

Key Points

Cite This Study

Understanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider